mAbxience | Portfolio: in constant progression
At mAbxience we are working to increase patient access to high quality medicines.
Highly attractive portfolio targeting the areas of hematology, oncology, osteoporosis and pediatrics.
With two approved products (MB01 rituximab and MB02 bevacizumab, since 2014 and 2016 respectively) and new products in development:
mAbxience develops biosimilars and biopharmaceutical products adhering to a strict “quality by design” standard, using the latest innovations in upstream & downstream and cutting-edge analytics.
Biosimilars are equivalent in terms of quality, safety and efficacy to the reference products. mAbxience guarantees the equivalence by subjecting the drugs to exhaustive comparability testing, regulated by the competent authorities. This ensures that our biosimilars are almost identical to the reference product with respect to structure, biological activity and overall performance of the final drug product.
In addition, clinical trials are conducted in accordance to the regulatory requirements, to establish similar clinical performance of the product development.